Literature DB >> 17507230

Chemical and biological effects of substitution of the 2-position of ring-expanded ('fat') nucleosides containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system: the role of electronic and steric factors on glycosidic bond stability and anti-HCV activity.

Peng Zhang1, Ning Zhang, Victor E Buckwold, Ramachandra S Hosmane.   

Abstract

The attempted removal of the aralkyl group of 2-bromo-1-p-methoxybenzyl-6-octylimidazo[4,5-e][1,3]diazepine (ZP-33) with trifluoroacetic acid resulted in replacement of the bromo group with a carbonyl at position-2 in addition to the desired deprotection at the 1-position. 2'-Deoxynucleosides of 2-bromo-substituted-imidazole-4,5-diesters (ZP-35 and ZP-103) were synthesized by direct glycosylation of the corresponding heterocycles. The attempted ring-closure of the above nucleosides resulted in deglycosylation to form the starting heterocycles. The 2-phenyl derivatives of the above nucleosides (ZP-45 and ZP-73) were successfully prepared by Suzuki coupling with the appropriate phenylboronic acids, but the attempted ring-closure with guanidines to form the desired 5,7-fused ring-expanded nucleosides (RENs) resulted once again in the formation of the corresponding heterocyclic aglycons (ZP-64 and ZP-75). The first successful 2-substituted REN (ZP-110) was synthesized by replacing the 2-deoxyribose sugar moiety with a ribosyl group and replacing the bromo group with a p-methoxyphenyl substituent at the 2-position. A number of imidazole riboside diester precursors containing a substituted phenyl group at the 2-position were synthesized in order to prepare analogues of ZP-110. The substituents on the phenyl ring included a variety of electron-donating or electron-withdrawing groups operating through inductive and/or resonance effects. However, the final ring-closure of the diesters with guanidines in order to prepare RENs was successful only in a limited number of cases, including the ones containing a p-fluorophenyl (ZP-121), a m-methoxyphenyl (ZP-122), or an unsubstituted phenyl (NZ-53) at the 2-position. Deglycosylation and incomplete ring-closure of the intermediates were the major problems encountered with most other cases. The stability of glycosidic bonds was found to be dependent on several factors including, but not limited to, the electron-donating inductive effect of the 2-phenyl substituents and the temperature of the reaction medium. The three target RENs ZP-110, ZP-121, and ZP-122 were screened for in vitro anti-HCV activity, employing an HCV RNA replicon assay. While ZP-121 was inactive, the other two compounds showed only weak anti-HCV activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507230      PMCID: PMC2754285          DOI: 10.1016/j.bmc.2007.04.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  16 in total

Review 1.  Improving anti-hepatitis C virus therapy.

Authors:  Stanislas Pol; Vincent O Mallet
Journal:  Expert Opin Biol Ther       Date:  2006-09       Impact factor: 4.388

2.  Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.

Authors:  Peng Zhang; Ning Zhang; Brent E Korba; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2005-10-05       Impact factor: 2.823

3.  Arylation of halogenated pyrimidines via a Suzuki coupling reaction.

Authors:  J M Schomaker; T J Delia
Journal:  J Org Chem       Date:  2001-10-19       Impact factor: 4.354

4.  Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

Authors:  Victor E Buckwold; Jiayi Wei; Zhuhui Huang; Chunsheng Huang; Aysegul Nalca; Jay Wells; Julie Russell; Barbara Collins; Roger Ptak; William Lang; Curtis Scribner; Dennis Blanchett; Tom Alessi; Peter Langecker
Journal:  Antiviral Res       Date:  2006-09-11       Impact factor: 5.970

5.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.

Authors:  J L Kim; K A Morgenstern; J P Griffith; M D Dwyer; J A Thomson; M A Murcko; C Lin; P R Caron
Journal:  Structure       Date:  1998-01-15       Impact factor: 5.006

Review 6.  West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.

Authors:  Edward B Hayes; Duane J Gubler
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 7.  Selective inhibitors of hepatitis C virus replication.

Authors:  Johan Neyts
Journal:  Antiviral Res       Date:  2006-06-23       Impact factor: 5.970

8.  Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus.

Authors:  Ning Zhang; Huan-Ming Chen; Verena Koch; Herbert Schmitz; Ching-Len Liao; Maria Bretner; Vishweshwar S Bhadti; Ali I Fattom; Robert B Naso; Ramachandra S Hosmane; Peter Borowski
Journal:  J Med Chem       Date:  2003-09-11       Impact factor: 7.446

9.  Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

Authors:  N Krieger; V Lohmann; R Bartenschlager
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 10.  Recent development of therapeutics for chronic HCV infection.

Authors:  Zhuhui Huang; Michael G Murray; John A Secrist
Journal:  Antiviral Res       Date:  2006-06-23       Impact factor: 5.970

View more
  1 in total

1.  Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.

Authors:  Sabindra K Samal; Samapika Routray; Ganesh Kumar Veeramachaneni; Rupesh Dash; Mahendran Botlagunta
Journal:  Sci Rep       Date:  2015-04-28       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.